At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
TRS01 eye drops +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-Masked, Randomized, Vehicle-controlled, Dose-ranging Study to Evaluate the Safety of TRS01 Eye Drops in Participants With Post-surgical Inflammation
In Brief
A Phase 2 clinical trial evaluating TRS01 eye drops and Placebo eye drops for Post Surgical Ocular Inflammation. Completed, enrolled 37 participants across 5 sites.
Detailed Summary
The objective of this study is to evaluate the safety and preliminary efficacy of TRS01 eye drops as compared to placebo on participants with ocular inflammation after cataract surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost Surgical Ocular Inflammation
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartFeb 2020
Primary CompletionJul 2020
TodayJul 2026
First PostedJan 10, 2020
Enrollment StartFeb 1, 2020
Primary CompletionJul 17, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.5 years ago
Interventions
TRS01 eye dropsdrug
Dosed 4 times a day (QID)
TRS01 eye dropsdrug
Dosed QID
TRS01 eye dropsdrug
Dosed QID
Placebo eye dropsdrug
Dosed QID